结核与肺部疾病杂志2024，Vol.5Issue(5)：489-494,6.DOI:10.19983/j.issn.2096-8493.2024107
哮喘表型和2型炎症哮喘研究进展
Research progress on the concept discrimination and treatment of type 2 inflammation in asthma
摘要
Abstract
Bronchial asthma(asthma)is a heterogeneous disease with multiple phenotypes based on differences in clinical features,triggers,airway inflammation,physiological and pathological features.The Global Initiative for Asthma(GINA)guidelines suggest that type 2 inflammation exists in asthma and can be diagnosed by testing for eosinophils,exhaled nitric oxide,and allergens.It has been found that 50％to 70％of asthma patients are related to type 2 inflammation,and the proportion of type 2 inflammation in severe asthma patients in China is more than 75％.Therefore,drug development and treatment for type 2 inflammation are critical.The authors review the concept,classification,pathogenesis,biomarkers and judgment criteria,asthma and the research progress of targeted therapy of type 2 inflammatory,and provides reference for the diagnostic and treatment of asthma biologics.关键词
炎症介导素类/支气管高反应性/哮喘/生物学标记Key words
Inflammation mediators/Bronchial hyperreactivity/Asthma/Biological markers分类
医药卫生引用本文复制引用
时旭,陈如冲,李靖..哮喘表型和2型炎症哮喘研究进展[J].结核与肺部疾病杂志,2024,5(5):489-494,6.基金项目
International(regional)Cooperation and Exchange Program(82161138020) 国际(地区)合作与交流项目(82161138020) （regional）
